01252nas a2200181   4500000000100000008004100001260001000042100001500052700001600067700001100083700001600094245005400110856005200164300001200216490000700228520082100235022001401056       2020                            d  bLepra1 aShrestha S1 aChaudhary S1 aGiri H1 aMarahatta S00aDapsone-induced optic atrophy: a rare case report  uhttps://leprosyreview.org/article/91/3/20-20020  a291-2940 v913 aDapsone-induced optic atrophy (OA) is very rare at therapeutic doses. A 43-year-old gentleman on WHO-recommended multibacillary Multi-Drug Therapy (WHO MB-MDT) containing rifampicin, dapsone, and clofazimine, presented with bilateral gradual painless diminution of vision after 3 months of medication. He denied any history of trauma, headache, limb weakness, ataxia, diplopia, temporal pain , or weight loss. There was no history of sudden diminution of vision in family members. Fundus examination showed bilateral pale optic discs with well-defined margins. Glucose-6-phosphate dehydrogenase (G6PD) was normal. He was diagnosed with OA secondary to dapsone. There is therefore a possibility of dapsone induced OA even at the therapeutic dose. Hence, we should perform routine eye check-up before starting dapsone.  a2162-8807